ALSO NOTED: Shire drug gets second approvable letter; Galapagos acquires ProStrakan sub; FDA asks Allergan for more data; and m

> The FDA has issued its second approvable letter for Shire's ADHD drug Vyvanse. Report

> Galapagos has acquired ProSkelia, a French subsidiary of ProStrakan in a deal worth up to €45 million. Report 

> Allergan has announced that the FDA has asked for more data on its eye pressure medication Combigan. Report

> The FDA has approved Novartis' Exforge for high blood pressure. Release

> Protiva Biotherapeutics has filed an appeal that seeks to overturn the BC Supreme Court's ruling that would permit Inex Pharmaceuticals Corporation to transfer the Inex-Protiva agreements to Tekmira Corporation without Protiva's consent. Release

And Finally... Drug reps will face a tough year in 2007. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.